Tech Company Inital Public Offerings
Pulmonx IPO
Operating out of Redwood City, Pulmonx is now a public company.
Transaction Overview
Company Name
Announced On
10/1/2020
Transaction Type
IPO
Amount
$190,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, the firm plans to use the net proceeds as follows:approximately $45 million to hire additional sales and marketing personnel and expand marketing programs in the United States, Europe and Asia Pacific to promote the sales of Zephyr Valves;approximately $15 million to fund product development and research and development activities;in accordance with the terms of the Oxford Agreement and based on the amount drawn thereunder, to pay a success fee of $1.9 million to Oxford on the closing of this offering; andthe remaining proceeds for working capital and general corporate purposes, including acquisitions or strategic investments in complementary businesses or technologies, although we do not currently have any plans for any such acquisitions or investments.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
700 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Pulmonx (Nasdaq: LUNG) is an innovative medical technology company engaged in the design, development and manufacture of therapeutic devices for the treatment of patients with severe emphysema.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/30/2020: Dewpoint Therapeutics venture capital transaction
Next: 10/1/2020: Talos venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs